COMMUNIQUÉS West-GlobeNewswire

Novartis announces change in Sandoz leadership
14/03/2019
Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced today that Richard Francis will [...]
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
14/03/2019
Enrollment Announced During MS Awareness Week NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular [...]
Extendicare Announces Exit from B.C. Market in 2020
14/03/2019
MARKHAM, Ontario, March 13, 2019 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it has received notice from Fraser Health and Vancouver Coastal Health, both [...]
Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 18, 2019
14/03/2019
RALEIGH, N.C., March 13, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation [...]
Protalix BioTherapeutics to Postpone the 2018 Financial Results and Corporate Update Conference Call
13/03/2019
CARMIEL, Israel, March 13, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
ADMA Biologics Reports Full Year 2018 Financial Results
13/03/2019
RAMSEY, N.J. and BOCA RATON, Fla., March 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin [...]
Zafgen to Present at the 31st Annual ROTH Conference
13/03/2019
BOSTON, March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
iCAD to Report Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results on Monday, March 18
13/03/2019
NASHUA, N.H., March 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial [...]
Axovant Sciences Announces Public Offering of Common Shares
13/03/2019
NEW YORK and BASEL, Switzerland, March 13, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the [...]
Harpoon Therapeutics to Participate in Upcoming William Blair Cancer Immunotherapy Conference
13/03/2019
SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that Gerald [...]
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
13/03/2019
SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]
miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook
13/03/2019
Cobomarsen tested in clinical trials for three different types of blood cancers Multiple clinical sites open and actively recruiting in the global Phase 2 SOLAR clinical trial of cobomarsen in CTCL Data from four [...]
Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time
13/03/2019
BASKING RIDGE, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the [...]
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019
13/03/2019
SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi- [...]
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
13/03/2019
~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ [...]
Sanofi successfully prices EUR 2 billion of bond issues
13/03/2019
Sanofi successfully prices EUR 2 billion of bond issues Paris, France - March 13, 2019 - Sanofi announces that it has successfully priced its offering of EUR 2 billion of notes (the " Notes ") across 3 tranches: €850 [...]
Sanofi place des emprunts obligataires de 2 milliards d'euros
13/03/2019
Sanofi place des emprunts obligataires de 2 milliards d'euros Paris, France - Le 13 mars 2019 - Sanofi annonce avoir placé avec succès une émission obligataire en 3 tranches (les « Obligations ») pour un montant de 2 [...]
Crossject : Résultats annuels 2018 et point d'activité
13/03/2019
Communiqué de Presse Résultats annuels et point d’activité Premiers lots cliniques au printemps Confirmation du calendrier de dépôt d’AMM Signature d’accords de licence prévus en 2019 Nouvelles perspectives commerciales [...]
FlexDex Provides Improved Solution to Prostate Surgery in Italy
13/03/2019
BRIGHTON, Mich., March 13, 2019 (GLOBE NEWSWIRE) -- FlexDex Inc. an innovative medical device company that has developed a platform technology to provide surgeons with high-performance and cost-effective minimally [...]

Pages